AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36534717 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% 2-chloroprocaine (CP)
Number of subjects: 40
Study 36534717 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:200,000 epinephrine and sodium bicarbonate (LEB)
Number of subjects: 40
Study 36534717 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 3 mg administered after delivery
Number of subjects: 40
Study 36534825 — intervention group
Group type: EXPERIMENTAL
Intervention: IFX s.c. 120 mg every 2 weeks
Number of subjects: 343
Study 36534825 — intervention group
Group type: COMPARATOR
Intervention: IFX i.v. 3 mg/kg every 8 weeks
Number of subjects: 343
Study 36534825 — intervention group
Group type: EXPERIMENTAL
Intervention: IFX s.c. post-switch
Number of subjects: 343
Study 36534825 — intervention group
Group type: COMPARATOR
Intervention: IFX i.v. post-switch
Number of subjects: 343
Study 36534825 — intervention group
Group type: EXPERIMENTAL
Intervention: IFX s.c. and i.v. (both)
Number of subjects: 343
Study 36534910 — intervention group
Group type: COMPARATOR
Intervention: Black patients
Number of subjects: 9088
Study 36534910 — intervention group
Group type: COMPARATOR
Intervention: Hispanic patients
Number of subjects: 9088
Study 36534910 — intervention group
Group type: EXPERIMENTAL
Intervention: White patients
Number of subjects: 9088
Study 36534942 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib (CZ) with chemotherapy
Number of subjects: 66
Study 36534976 — intervention group
Group type: EXPERIMENTAL
Intervention: DART (Decision-Aid for Renal Therapy)
Number of subjects: 400
Study 36534976 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study 36535011 — intervention group
Group type: EXPERIMENTAL
Intervention: eltrombopag
Number of subjects: 96
Study 36535011 — intervention group
Group type: EXPERIMENTAL
Intervention: rh-TPO
Number of subjects: 96
Study 36535116 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus olanzapine
Number of subjects: 126
Study 36535116 — intervention group
Group type: COMPARATOR
Intervention: Sertraline plus placebo
Number of subjects: 126
Study 36535196 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy (5 × 5 Gy in one week)
Number of subjects: 103
Study 36535196 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy (50 Gy, 2 Gy/f, 5 weeks with capecitabine: 800 mg/m2)
Number of subjects: 103
Study 36535196 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy
Number of subjects: 103
Study 36535196 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy
Number of subjects: 103
Study 36535196 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy and Chemoradiotherapy
Number of subjects: 103
Study 36535300 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg daily
Number of subjects: 296
Study 36535300 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 296
Study 36535300 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 296
Study 36535300 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 296
Study 36535524 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 or 300 mg every 2 weeks up to 52 weeks
Number of subjects: 0
Study 36535524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36535535 — intervention group
Group type: EXPERIMENTAL
Intervention: Venglustat 8mg
Number of subjects: 478
Study 36535535 — intervention group
Group type: EXPERIMENTAL
Intervention: Venglustat 15mg
Number of subjects: 478
Study 36535535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478
Study 36535535 — intervention group
Group type: EXPERIMENTAL
Intervention: Venglustat 8mg or 15mg
Number of subjects: 478
Study 36535606 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 318
Study 36535606 — intervention group
Group type: COMPARATOR
Intervention: Attention/social contact control
Number of subjects: 318
Study 36535643 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma endotrophin levels in KTRs
Number of subjects: 690
Study 36535643 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma endotrophin levels before and after kidney transplantation
Number of subjects: 690
Study 36535749 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mean IOP
Number of subjects: 62
Study 36535749 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak IOP
Number of subjects: 62
Study 36535749 — intervention group
Group type: EXPERIMENTAL
Intervention: IOP fluctuation (IOP SD)
Number of subjects: 62
Study 36535749 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mean IOP in eyes with peak <18 mm Hg
Number of subjects: 62
Study 36535765 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention with individualized exercise prescription and mHealth device providing heart rate-based just-in-time (JIT) feedback on PA intensity.
Number of subjects: 44
Study 36535765 — intervention group
Group type: COMPARATOR
Intervention: Healthy aging education condition with a reading prescription and weekly quizzes.
Number of subjects: 44
Study 36535779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor with Aspirin
Number of subjects: 6412
Study 36535779 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel with Aspirin
Number of subjects: 6412
Study 36535801 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-based confocal laser endomicroscopy (nCLE) during robotic bronchoscopy
Number of subjects: 20
Study 36535990 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectralis device (20° × 20°, 25 B-scans; 30° × 25°, 241 B-scans)
Number of subjects: 200
Study 36535990 — intervention group
Group type: COMPARATOR
Intervention: Cirrus device (200 × 200 macular cube, 6 × 6 mm)
Number of subjects: 200
Study 36535990 — intervention group
Group type: COMPARATOR
Intervention: Less dense scans
Number of subjects: 200
Study 36536016 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention package including monthly food vouchers for eggs, milk, semolina, sugar, and oil, multiple micronutrient powder (MNP), counseling on child feeding and handwashing.
Number of subjects: 412
Study 36536016 — intervention group
Group type: COMPARATOR
Intervention: Regular government health communication alone (control).
Number of subjects: 412
Study 36536050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular comorbidities
Number of subjects: 0
Study 36536050 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function (FEV1)
Number of subjects: 0
Study 36536093 — intervention group
Group type: EXPERIMENTAL
Intervention: abobotulinumtoxinA 50 units
Number of subjects: 520
Study 36536093 — intervention group
Group type: COMPARATOR
Intervention: placebo (saltwater)
Number of subjects: 520
Study 36536093 — intervention group
Group type: COMPARATOR
Intervention: onabotulinumtoxinA 20 units
Number of subjects: 520
Study 36536114 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (0.25 g/kg fat free mass)
Number of subjects: 50
Study 36536114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricket protein (0.25 g/kg fat free mass)
Number of subjects: 50
Study 36536114 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea protein (0.25 g/kg fat free mass)
Number of subjects: 50
Study 36536114 — intervention group
Group type: COMPARATOR
Intervention: Whey protein
Number of subjects: 50
Study 36536114 — intervention group
Group type: COMPARATOR
Intervention: Cricket protein
Number of subjects: 50
Study 36536114 — intervention group
Group type: COMPARATOR
Intervention: Pea protein
Number of subjects: 50
Study 36536249 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic tilt-table verticalization with functional electrical stimulation (FES)
Number of subjects: 47
Study 36536249 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic tilt-table verticalization without functional electrical stimulation (FES)
Number of subjects: 47
Study 36536249 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (CPT)
Number of subjects: 47
Study 36536249 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (RTT with FES, RTT without FES, CPT)
Number of subjects: 47
Study 36536249 — intervention group
Group type: EXPERIMENTAL
Intervention: Verticalization/mobilization time
Number of subjects: 47
Study 36536268 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-choice applied knowledge measure
Number of subjects: 30
Study 36536268 — intervention group
Group type: COMPARATOR
Intervention: Role-play A (easier role-play)
Number of subjects: 30
Study 36536268 — intervention group
Group type: COMPARATOR
Intervention: Role-play B (more difficult role-play)
Number of subjects: 30
Study 36536333 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen with PRP (Group A, n=30)
Number of subjects: 90
Study 36536333 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen alone (Group B, n=30)
Number of subjects: 90
Study 36536333 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP alone (Group C, n=30)
Number of subjects: 90
Study 36536333 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 90
Study 36536364 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 2 g per day for 8 weeks
Number of subjects: 0
Study 36536403 — intervention group
Group type: EXPERIMENTAL
Intervention: CD3+ T cells prepared from cryopreserved PBMC
Number of subjects: 0
Study 36536403 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 36536470 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer of day 6 blastocysts on the 7th day of progesterone supplementation
Number of subjects: 900
Study 36536470 — intervention group
Group type: COMPARATOR
Intervention: Transfer of day 6 blastocysts on the 6th day of progesterone supplementation
Number of subjects: 900
Study 36536472 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab
Number of subjects: 29
Study 36536625 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis audio file
Number of subjects: 46
Study 36536625 — intervention group
Group type: COMPARATOR
Intervention: Placebo audio file
Number of subjects: 46
Study 36536736 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) fluorescence angiography
Number of subjects: 30
Study 36536916 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (single dose)
Number of subjects: 1
Study 36537193 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain and Symptom Assessment Tool (Widespread Pain Index - WPI; 0-18 pain locations)
Number of subjects: 203
Study 36537193 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Severity checklist (SS; 0-12)
Number of subjects: 203
Study 36537193 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measures of pain intensity, functional impairment, and psychological functioning
Number of subjects: 203
Study 36537193 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of WPI and SS scores
Number of subjects: 203
Study 36537193 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of psychological factors
Number of subjects: 203
Study 36537204 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobocertinib (160 mg once daily)
Number of subjects: 257
Study 36537290 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) using a lumen-apposing metal stent (LAMS)
Number of subjects: 30
Study 36537346 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-47D11 (180, 600, or 2400 mg)
Number of subjects: 0
Study 36537346 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-47D11 (600 mg or higher)
Number of subjects: 0
Study 36537346 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-47D11 (any dose)
Number of subjects: 0
Study 36537346 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-47D11
Number of subjects: 0
Study 36537360 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysubstance use
Number of subjects: 0
Study 36537360 — intervention group
Group type: COMPARATOR
Intervention: Alcohol only
Number of subjects: 0
Study 36537742 — intervention group
Group type: EXPERIMENTAL
Intervention: KN015 (20 μg)
Number of subjects: 0
Study 36537742 — intervention group
Group type: EXPERIMENTAL
Intervention: KN015 (40 μg)
Number of subjects: 0
Study 36537742 — intervention group
Group type: EXPERIMENTAL
Intervention: KN015 (60 μg)
Number of subjects: 0
Study 36537742 — intervention group
Group type: EXPERIMENTAL
Intervention: KN015
Number of subjects: 0
Study 36537742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36537785 — intervention group
Group type: EXPERIMENTAL
Intervention: Green kiwifruit (2 kiwifruits per day)
Number of subjects: 184
Study 36537785 — intervention group
Group type: COMPARATOR
Intervention: Psyllium (7.5 g per day)
Number of subjects: 184
Study 36537851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted resection
Number of subjects: 34
Study 36537851 — intervention group
Group type: COMPARATOR
Intervention: Conventional resection
Number of subjects: 34
Study 36537898 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical Thickness Index (CTI) with cutoff ≤0.50
Number of subjects: 247
Study 36537898 — intervention group
Group type: COMPARATOR
Intervention: DXA T-score at total hip
Number of subjects: 247
Study 36537898 — intervention group
Group type: COMPARATOR
Intervention: DXA T-score at femoral neck
Number of subjects: 247
Study 36537898 — intervention group
Group type: COMPARATOR
Intervention: DXA T-score at lumbar spine
Number of subjects: 247
Study 36537898 — intervention group
Group type: COMPARATOR
Intervention: DXA T-score at forearm
Number of subjects: 247
Study 36538094 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival air-polishing with erythritol powder
Number of subjects: 40
Study 36538094 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 40
Study 36538098 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment (no specific treatment for hypersalivation)
Number of subjects: 130
Study 36538139 — intervention group
Group type: EXPERIMENTAL
Intervention: Resiliency intervention
Number of subjects: 24
Study 36538160 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36538166 — intervention group
Group type: EXPERIMENTAL
Intervention: High-loading intervention (training at ~90% of the MVC) (n=15)
Number of subjects: 39
Study 36538166 — intervention group
Group type: COMPARATOR
Intervention: Eccentric exercise (according to the Alfredson protocol) (n=15)
Number of subjects: 39
Study 36538166 — intervention group
Group type: COMPARATOR
Intervention: Passive therapy (n=14)
Number of subjects: 39
Study 36538189 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + High-Intensity Laser Therapy (HILT)
Number of subjects: 108
Study 36538189 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Dry Needling
Number of subjects: 108
Study 36538189 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 108
Study 36538259 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitazalimab (600 μg/kg)
Number of subjects: 95
Study 36538259 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitazalimab (2000 μg/kg)
Number of subjects: 95
Study 36538259 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitazalimab (with corticosteroids)
Number of subjects: 95
Study 36538259 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitazalimab (without corticosteroids)
Number of subjects: 95
Study 36538259 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitazalimab
Number of subjects: 95
Study 36538311 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker-delivered hearing care intervention (n=78)
Number of subjects: 151
Study 36538311 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n=73)
Number of subjects: 151
Study 36538309 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE care model (risk-stratified, multidisciplinary intervention combining physical therapy, health coach counseling, and specialist consultation)
Number of subjects: 2971
Study 36538309 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized postural therapy (IPT, combining physical therapy with self-efficacy and self-management)
Number of subjects: 2971
Study 36538309 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2971
Study 36538328 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weekly, 30-minute virtual health coach sessions + 11 weekly cooking videos and associated home-delivered groceries
Number of subjects: 123
Study 36538333 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Gait Assessment (FGA)
Number of subjects: 53
Study 36538333 — intervention group
Group type: EXPERIMENTAL
Intervention: High Level Mobility Assessment Tool (HiMAT)
Number of subjects: 53
Study 36538333 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Item Hybrid Assessment of Mobility for mTBI (HAM-4-mTBI)
Number of subjects: 53
Study 36538383 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument-assisted soft-tissue mobilization (IASTM)
Number of subjects: 39
Study 36538383 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 39
Study 36538383 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 36538392 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Number of subjects: 38
Study 36538392 — intervention group
Group type: COMPARATOR
Intervention: Control (no taping)
Number of subjects: 38
Study 36538409 — intervention group
Group type: EXPERIMENTAL
Intervention: ExPlas (exercise-trained plasma) transfusion from young, healthy, fit adults, administered once a month for 4 months.
Number of subjects: 30
Study 36538409 — intervention group
Group type: EXPERIMENTAL
Intervention: ExPlas (exercise-trained plasma) transfusion
Number of subjects: 30
Study 36538418 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground locomotor training (OLT)
Number of subjects: 12
Study 36538580 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter AVR
Number of subjects: 3403
Study 36538580 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical AVR
Number of subjects: 3403
Study 36538580 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite rehospitalization (heart failure, valve-related, or procedure-related causes)
Number of subjects: 3403
Study 36538580 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure hospitalization after AVR
Number of subjects: 3403
Study 36538580 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure hospitalization and rehospitalization after AVR
Number of subjects: 3403
Study 36538596 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality and multiparametric model combining 2 imaging indices with natriuretic peptides (BNP or NT-proBNP)
Number of subjects: 127
Study 36538596 — intervention group
Group type: COMPARATOR
Intervention: Current echocardiography-based indications for aortic regurgitation surgery
Number of subjects: 127
Study 36538630 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass or vertical sleeve gastrectomy
Number of subjects: 217
Study 36538782 — intervention group
Group type: EXPERIMENTAL
Intervention: Soticlestat (100 mg twice daily, titrated up to 300 mg twice daily)
Number of subjects: 24
Study 36538782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 36538782 — intervention group
Group type: EXPERIMENTAL
Intervention: Soticlestat
Number of subjects: 24
Study 36539060 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced retention strategies
Number of subjects: 244
Study 36539060 — intervention group
Group type: COMPARATOR
Intervention: Standard retention strategies (non-retention group)
Number of subjects: 244
Study 36539060 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention strategies exposure
Number of subjects: 244
Study 36539060 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline executive function composite score
Number of subjects: 244
Study 36539060 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain diagnosis
Number of subjects: 244
Study 36539061 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Best Practices (TBP) - evidence-based COVID-19 infection prevention practices adapted for residents with SMI and ID/DD and GH staff.
Number of subjects: 400
Study 36539061 — intervention group
Group type: COMPARATOR
Intervention: General Best Practices (GBP) - required standard of care reflecting state and federal standard general guidelines for COVID-19 prevention in GHs.
Number of subjects: 400
Study 36539157 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning exercise (AMEx) at 10:30
Number of subjects: 16
Study 36539157 — intervention group
Group type: COMPARATOR
Intervention: Evening exercise (PMEx) at 18:30
Number of subjects: 16
Study 36539217 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 40
Study 36539217 — intervention group
Group type: COMPARATOR
Intervention: SMILE
Number of subjects: 40
Study 36539568 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula therapy
Number of subjects: 30
Study 36539568 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure
Number of subjects: 30
Study 36539590 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty index (deficit accumulation)
Number of subjects: 100
Study 36539711 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/hour intravenous clazosentan
Number of subjects: 400
Study 36539711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 36539734 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) group
Number of subjects: 140
Study 36539734 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU) group
Number of subjects: 140
Study 36539736 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse (0.12% chlorhexidine gluconate, gargled for 1 minute with 100 mL)
Number of subjects: 106
Study 36539736 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no chlorhexidine mouthrinse)
Number of subjects: 106
Study 36539736 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse
Number of subjects: 106
Study 36539736 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 106
Study 36539741 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and practice in family involvement
Number of subjects: 75